

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number 10/596,429	
Date Submitted: August 3, 2006		Filing Date 12/17/2004	
(use as many sheets as necessary)		First Named Inventor Norihiro NISHIMOTO	
		Group Art Unit Unassigned	
		Examiner Name Unassigned	
		Attorney Docket Number 053466-0417	
Sheet	1	of	1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	JP	10324639	A	Mihara MASAHIKO	12/08/1998	Abstract	
	A2	JP	2003026699	A	Yoshizaki KAZUYUKI et al.	01/29/2003	Abstract	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B1	Hiroshi HASHIMOTO, "Surveillance Study on Intractable Angitis Comprehensive Research Report in a Financial Year", Heisei 13, March 2002, pp. 47-55, full text with translation.	
	B2	Shunsei HIROHATA et al., "Elevation of Cerebrospinal Fluid Interleukin-6 Activity in Patients with Vasculitides and Central Nervous System Involvement", Clinical Immunology and Immunopathology, Vol. 66, No. 3, March, pp. 225-229, 1993.	
	B3	Marina NORIS et al., "Interleukin-6 and RANTES in Takayasu Arteritis", Circulation, July 6, 1999, pp. 55- 60.	
	B4	Norihiro NISHIMOTO, "Approach for Therapy in the Near Future -Focusing around the Anti-Cytokine Therapy", medicina, vol. 38, No. 3, March 2001, pp.441-445, full text with translation.	
	B5	Ryuji KOIKE, "Systemic erythematosus (SLE) and antiphospholipid antibody syndrome", medicina, vol. 35, no. 10, October 1998, pp. 1728-1730, full text with translation.	
	B6	International Search Report	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

Examiner Signature	/Lorraine Spector/	Date Considered	06/06/2011
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.